Skip to main content

Table 1 Patient characteristics

From: Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps

Age mean (SD)

52.94 (10)

Female Sex n (%)

24 (45.28)

AERD n (%)

20 (37.73)

Asthma n (%)

47 (88.67)

Dust Mite Sensitivity n (%)

26 (49.05)

Prior Sinus Surgery/Polypectomy n (%)

48 (90.56)

 Endoscopic Sinus Surgery or in clinic polypectomy

46 (86.73)

 Endoscopic Sinus Surgery and in clinic Polypectomy

2 (3.77)

Number of prior surgeries mean (range)

2.57 (0–16)

Time since last surgery to start of therapy—months (SD)

49.55 (34.21)

Baseline SNOT-22 score mean (SD)

60.56 (21.63)

Average number of doses received up to Jan 31, 2022 n(range)

23 (4–36)

  1. AERD, Aspirin Exacerbated Respiratory Disease; SNOT-22, Sinonasal Outcome Test -22; SD, Standard deviation